Patents by Inventor Mats Nagard

Mats Nagard has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • MGluR5 modulators I
    Patent number: 7678796
    Abstract: The present invention is directed to novel compounds, to a process for their preparation, their use in therapy and pharmaceutical compositions comprising the novel compounds.
    Type: Grant
    Filed: April 25, 2007
    Date of Patent: March 16, 2010
    Assignee: AstraZeneca AB
    Inventors: Andreas Wallberg, Karolina Nilsson, Björn Holm, Mats Nagard, Kenneth Granberg, Abdelmalik Slassi, Louise Edwards, Methvin Isaac, Tao Xin, Tomislav Stefanac
  • THIOPHENE 1,2,4-TRIAZOLE DERIVATIVES AS MODULATORS OF MGLUR5
    Publication number: 20090111825
    Abstract: The present invention is directed to novel compounds, to a process for their preparation, their use in therapy and pharmaceutical compositions comprising the novel compounds.
    Type: Application
    Filed: October 24, 2008
    Publication date: April 30, 2009
    Inventors: Kenneth GRANBERG, Bjorn Holm, Mats Nagard
  • 1,2,4-TRIAZOLE ETHER DERIVATIVES AS MODULATORS OF MGLUR5
    Publication number: 20090111857
    Abstract: The present invention is directed to novel compounds, to a process for their preparation, their use in therapy and pharmaceutical compositions comprising the novel compounds.
    Type: Application
    Filed: October 24, 2008
    Publication date: April 30, 2009
    Applicant: AstraZeneca AB
    Inventors: Peter DOVE, Kenneth Granberg, Methvin Isaac, Mats Nagard, Abdelmalik Slassi
  • AMIDE LINKED HETEROAROMATIC DERIVATIVES AS MODULATORS OF MGLUR5
    Publication number: 20090111824
    Abstract: The present invention is directed to novel compounds, to a process for their preparation, their use in therapy and pharmaceutical compositions comprising the novel compounds.
    Type: Application
    Filed: October 24, 2008
    Publication date: April 30, 2009
    Applicant: AstraZeneca AB
    Inventors: Emma Bratt, Kenneth Granberg, Methvin Isaac, Mats Nagard, Abdelmalik Slassi
  • Use
    Publication number: 20090054491
    Abstract: The present invention relates to the use of compounds of formula II for the treatment or prevention of obesity.
    Type: Application
    Filed: June 19, 2006
    Publication date: February 26, 2009
    Applicant: AstraZeneca AB
    Inventors: Louise Edwards, Methvin Isaac, Abdelmalik Slassi, Mats Nagard, Leonard Storlien, David Morgan
  • MGluR5 modulators VI
    Publication number: 20070259895
    Abstract: The present invention is directed to novel compounds, to a process for their preparation, their use in therapy and pharmaceutical compositions comprising the novel compounds.
    Type: Application
    Filed: April 25, 2007
    Publication date: November 8, 2007
    Applicants: AstraZeneca AB, NPS PHARMACEUTICALS, INC.
    Inventors: Methvin Isaac, Abdelmalik Slassi, Louise Edwards, Tao Xin, Tomislav Stefanac, Peter Dove, Mats Nagard
  • MGluR5 modulators I
    Publication number: 20070259862
    Abstract: The present invention is directed to novel compounds, to a process for their preparation, their use in therapy and pharmaceutical compositions comprising the novel compounds.
    Type: Application
    Filed: April 25, 2007
    Publication date: November 8, 2007
    Applicants: AstraZeneca AB, NPS PHARMACEUTICALS, INC.
    Inventors: Andreas Wallberg, Karolina Nilsson, Bjorn Holm, Mats Nagard, Kenneth Granberg, Abdelmalik Slassi, Louise Edwards, Methvin Isaac, Tao Xin, Tomislav Stefanac
  • Pyridin-2-one compounds useful as inhibitors of thrombin
    Publication number: 20070161643
    Abstract: There is provided a compound of formula I wherein the dashed line, R1, R2, R3a, R3b, A, D, E, G and L have meanings given in the description, which compounds are useful as, or are useful as prodrugs of, competitive inhibitors of trypsin-like proteases, such as thrombin, and thus, in particular, in the treatment of conditions where inhibition of thrombin is beneficial (e.g. conditions, such as thrombo-embolisms, where inhibition of thrombin is required or desired, and/or conditions where anticoagulant therapy is indicated).
    Type: Application
    Filed: February 2, 2005
    Publication date: July 12, 2007
    Inventors: Malken Bayrakdarian, Kristina Berggren, Ojvind Davidsson, Ola Fjellstrom, David Gustafsson, Stephen Hanessian, Tord Inghardt, Ingemar Nilsson, Mats Nagard, Daniel Simard, Eric Therrien
  • 5,6-Dihydropyrin-2-one compounds useful as inhibitors of thrombin
    Publication number: 20070099962
    Abstract: There is provided a compound of formula (I) wherein R1, R2a, R2b, R3a, R3b, R4, R5, R6, A, G and L have meanings given in the description, which compounds are useful as, or are useful as prodrugs of, competitive inhibitors of trypsin-like proteases, such as trombin, and thus, in particular, in the treatment of conditions where inhibition of thrombin is beneficial (e.g. conditions, such as thrombo-embolisms, where inhibition of trombin is required or desired, and/or conditions whereas anticoagulant therapy is indicated).
    Type: Application
    Filed: December 15, 2004
    Publication date: May 3, 2007
    Inventors: Kristina Berggren, Ojvind Davidsson, Ola Fjellstrom, David Gustafsson, Stephen Hanessian, Tord Inghardt, Mats Nagard, Ingemar Nilsson, Eric Therrien, Willem Van Otterlo
  • 1,5-Diaryl-pyrrole-3-carboxamide derivatives and their use as cannabinoid receptor modulators
    Publication number: 20060122230
    Abstract: The present invention relates to a compound of formula (I) in which R1 and R2 independently represent phenyl, thienyl or pyridyl each of which is optionally substituted by one, two or three groups represented by Z; and R3 is H, a C1-3alkyl group, a C1-3alkoxymethyl group, trifluoromethyl, a hydroxyC1-3alkyl group, an aminoC1-3alkyl group, C1-3alkoxycarbonyl, carboxy, cyano, carbamoyl, mono or di C1-3alkylcarbamoyl, acetyl, or hydrazinocarbonyl of formula —CONHNRaRb wherein Ra and Rb are as defined for R4 and R5 respectively; X is CO or SO2; Y is absent or represents NH optionally substituted by a C1-3alkyl group; R4 and R5 independently represent: a C1-6alkyl group; an (amino)C1-4alkyl-group in which the amino is optionally substituted by one or more C1-3alkyl groups; an optionally substituted non-aromatic C3-15carbocyclic group; a (C3-12cycloalkyl)C1-3alkyl-group; a group —(CH2)r(phenyl)s; naphthyl; anthracenyl; a saturated 5 to 8 membered heterocyclic group containing one nitrogen and optionally one of the
    Type: Application
    Filed: December 18, 2003
    Publication date: June 8, 2006
    Applicant: AstraZeneca AB
    Inventors: Anna Berggren, Stig Bosfrom, Leifeng Cheng, Stig Elebring, Peter Greasley, Mats Nagard, Johan Wilstermann, Emma Terricabras